Show simple item record

AuthorGorachinov, Filip
AuthorMraiche, Fatima
AuthorMoustafa, Diala Alhaj
AuthorHishari, Ola
AuthorIsmail, Yomna
AuthorJoseph, Jensa
AuthorCrcarevska, Maja Simonoska
AuthorDodov, Marija Glavas
AuthorGeskovski, Nikola
AuthorGoracinova, Katerina
Available date2023-05-04T05:56:23Z
Publication Date2023-02-22
Publication NameBeilstein Journal of Nanotechnology
Identifierhttp://dx.doi.org/10.3762/bjnano.14.23
CitationGorachinov, F., Mraiche, F., Moustafa, D. A., Hishari, O., Ismail, Y., Joseph, J., ... & Goracinova, K. (2023). Nanotechnology–a robust tool for fighting the challenges of drug resistance in non-small cell lung cancer. Beilstein Journal of Nanotechnology, 14(1), 240-261.
ISSN2190-4286
URIhttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85150911005&origin=inward
URIhttp://hdl.handle.net/10576/42315
AbstractGenomic and proteomic mutation analysis is the standard of care for selecting candidates for therapies with tyrosine kinase inhibitors against the human epidermal growth factor receptor (EGFR TKI therapies) and further monitoring cancer treatment efficacy and cancer development. Acquired resistance due to various genetic aberrations is an unavoidable problem during EGFR TKI therapy, leading to the rapid exhaustion of standard molecularly targeted therapeutic options against mutant variants. Attacking multiple molecular targets within one or several signaling pathways by co-delivery of multiple agents is a viable strategy for overcoming and preventing resistance to EGFR TKIs. However, because of the difference in pharmacokinetics among agents, combined therapies may not effectively reach their targets. The obstacles regarding the simultaneous co-delivery of therapeutic agents at the site of action can be overcome using nanomedicine as a platform and nanotools as delivery agents. Precision oncology research to identify targetable biomarkers and optimize tumor homing agents, hand in hand with designing multifunctional and multistage nanocarriers that respond to the inherent heterogeneity of the tumors, may resolve the challenges of inadequate tumor localization, improve intracellular internalization, and bring advantages over conventional nanocarriers
Languageen
PublisherBeilstein-Institut Zur Forderung der Chemischen Wissenschaften
Subjectco-delivery nanoparticles
combinatorial therapy
EGFR TKI resistance
non-small cell lung cancer (NSCLC)
overcoming and preventing resistance
TitleNanotechnology – a robust tool for fighting the challenges of drug resistance in non-small cell lung cancer
TypeArticle
Pagination240-261
Volume Number14
dc.accessType Open Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record